Chromosomal translocations occur in leukemias, lymphomas, sarcomas and some epithelial tumors and some generate unique fusion proteins. These translocation products may provide tumor-specific targets for the development of new therapeutic strategies tailored to a malignant cell.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells
Nature Communications Open Access 08 October 2020
-
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
Nature Communications Open Access 09 August 2018
-
Oncogenic fusion proteins adopt the insulin-like growth factor signaling pathway
Molecular Cancer Open Access 19 February 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rabbitts, T.H. Chromosomal translocations in human cancer. Nature 372, 143–149 (1994).
Pabo, C.O., Peisach, E. & Grant, R.A. Design and selection of novel Cys2His2 zinc finger proteins. Ann. Rev. Biochem. 70, 313–340 (2001).
Gottesfeld, J.M., Neely, L., Trauger, J.W., Baird, E.E. & Dervan, P.B. Regulation of gene expression by small molecules. Nature 387, 202–205 (1997).
Stocks, M.R. & Rabbitts, T.H. Masked antisense: a molecular configuration for discriminating similar RNA targets. EMBO Reports 11, 59–64 (2000).
Kuwabara, T. et al. A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo. Mol. Cell 2, 617–627 (1998).
Ullu, E., Djikeng, A., Shi, H. & Tschudi, C. RNA interference: advances and questions. Philos. Trans. R. Soc. Lond. B Biol. Sci. 357, 65–70 (2002).
Pinilla-Ibarz, J., Cathcart, K. & Scheinberg, D.A. CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev. 14, 111–120 (2000).
Druker, B. Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia. Semin. Hematol. 38, 9–14 (2001).
Cattaneo, A. & Biocca, S. The selection of intracellular antibodies. Trends Biotech. 17, 115–121 (1999).
Tanaka, T. & Rabbitts, T.H. Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation. EMBO J. (in the press).
Geyer, C.R. & Brent, R. Selection of genetic agents from random peptide aptamer expression libraries. Methods Enzymol. 328, 171–208 (2000).
He, L.Z. et al. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nat. Genet. 18, 126–135 (1998).
Adams, J.M. & Cory, S. Transgenic models of tumor development. Science 254, 1161–1167 (1991).
Ayton, P.M. & Cleary, M.L. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene Rev. 20, 5695–5707 (2001).
Yergeau, D.A. et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat. Genet. 15, 303–306 (1997).
Buchholz, F., Refaeli, Y., Trumpp, A. & Bishop, J.M. Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse. EMBO Reports 1, 133–139 (2000).
Collins, E.C., Pannell, R., Simpson, E.M., Forster, A. & Rabbitts, T.H. Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-loxP in mouse development. EMBO Reports 1, 127–132 (2000).
Higuchi, M. et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1, 63–74 (2002).
Tse, E. & Rabbitts, T.H. Intracellular antibody-caspase mediated cell killing: a novel approach for application in cancer therapy. Proc. Natl. Acad. Sci. USA 97, 12266–12271 (2000).
Elliott, G. & O'Hare, P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88, 223–233 (1997).
Derossi, D., Chassaing, G. & Prochiantz, A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol. 8, 84–87 (1998).
Becker-Hapak, M., McAllister, S.S. & Dowdy, S.F. TAT-mediated protein transduction into mammalian cells. Methods 24, 247–256 (2001).
Darnell, J.E. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2, 740–749 (2002).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T.H.R. is a consultant for Iclectus Ltd. M.R.S. is an employee of Iclectus Ltd.
Rights and permissions
About this article
Cite this article
Rabbitts, T., Stocks, M. Chromosomal translocation products engender new intracellular therapeutic technologies. Nat Med 9, 383–386 (2003). https://doi.org/10.1038/nm0403-383
Issue Date:
DOI: https://doi.org/10.1038/nm0403-383
This article is cited by
-
In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells
Nature Communications (2020)
-
Oncogenic fusion proteins adopt the insulin-like growth factor signaling pathway
Molecular Cancer (2018)
-
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
Nature Communications (2018)
-
ERG gene rearrangement status in prostate cancer detected by immunohistochemistry
Virchows Archiv (2011)
-
EWS-Oct-4B, an alternative EWS-Oct-4 fusion gene, is a potent oncogene linked to human epithelial tumours
British Journal of Cancer (2010)